Evoke Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal disorders and diseases. It develops, commercializes and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Gimoti is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti offers systemic delivery by nasal spray administration. It has developed a nasal formulation of metoclopramide to provide its targeted patient population with recurrent symptoms of diabetic gastroparesis with a product that is systemically delivered as an alternative to the oral or intravenous routes of administration. The nasal formulation delivers metoclopramide to patients with delayed gastric emptying and/or frequent vomiting.
公司代码EVOK
公司名称Evoke Pharma Inc
上市日期Sep 25, 2013
CEOD'Onofrio (Matthew J)
员工数量3
证券类型Ordinary Share
年结日Sep 25
公司地址420 Stevens Avenue
城市SOLANA BEACH
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编92075
电话18583451494
网址https://evokepharma.com/
公司代码EVOK
上市日期Sep 25, 2013
CEOD'Onofrio (Matthew J)